{"hands_on_practices": [{"introduction": "Before we can assess the clinical impact of *CYP2C19* variants, we must first understand their prevalence. The Hardy-Weinberg equilibrium (HWE) principle is a fundamental tool in population genetics that allows us to estimate genotype frequencies from known allele frequencies, assuming a set of ideal conditions. This exercise [@problem_id:4327675] provides a practical application of HWE to predict the proportion of individuals in a population who are intermediate and poor metabolizers of clopidogrel, setting the stage for understanding the scale of this pharmacogenomic issue.", "problem": "A pharmacogenomics laboratory is validating a population-level model for the gene Cytochrome P450 Family 2 Subfamily C Member 19 (CYP2C19) to inform clopidogrel response phenotypes. Consider a bi-allelic approximation at the CYP2C19 locus with a normal-function allele denoted as $\\ast 1$ and a loss-of-function allele denoted as $\\ast 2$. Assume an autosomal, diploid organism with random mating, no selection, no migration, no mutation, and no genotyping error. Let the population allele frequency of the loss-of-function allele be $q = p(\\ast 2) = 0.15$, and assume Hardy–Weinberg equilibrium (HWE). Let the normal-function allele frequency be $p = p(\\ast 1) = 1 - q$.\n\nPhenotype mapping follows standard clinical pharmacogenetics classification: individuals with genotype $\\ast 1 / \\ast 2$ are intermediate metabolizers (IM) and individuals with genotype $\\ast 2 / \\ast 2$ are poor metabolizers (PM) for clopidogrel activation. Ignore other star alleles such as $\\ast 3$ or $\\ast 17$ for this model.\n\nUsing only the HWE framework and these assumptions, compute the expected genotype frequencies for $\\ast 1 / \\ast 1$, $\\ast 1 / \\ast 2$, and $\\ast 2 / \\ast 2$, and from these identify the population proportions of IM and PM. Express the IM and PM proportions as decimals and round your final values to four significant figures. Report your final answer as a $1 \\times 2$ row, in the order $\\text{IM}, \\text{PM}$, with no units.", "solution": "The fundamental base is the Hardy–Weinberg principle for a bi-allelic autosomal locus under random mating and the absence of evolutionary forces. If the allele frequencies are $p = p(\\ast 1)$ and $q = p(\\ast 2)$ with $p + q = 1$, then the expected genotype frequencies are:\n- $\\ast 1 / \\ast 1$ with frequency $p^{2}$,\n- $\\ast 1 / \\ast 2$ with frequency $2 p q$,\n- $\\ast 2 / \\ast 2$ with frequency $q^{2}$.\n\nWe are given $q = 0.15$, so $p = 1 - q = 1 - 0.15 = 0.85$.\n\nCompute each genotype frequency:\n1. $\\ast 1 / \\ast 1$: $p^{2} = (0.85)^{2} = 0.7225$.\n2. $\\ast 1 / \\ast 2$: $2 p q = 2 \\times 0.85 \\times 0.15 = 2 \\times 0.1275 = 0.255$.\n3. $\\ast 2 / \\ast 2$: $q^{2} = (0.15)^{2} = 0.0225$.\n\nPhenotype mapping:\n- Intermediate metabolizer (IM) corresponds to the heterozygous genotype $\\ast 1 / \\ast 2$, thus proportion $2 p q = 0.255$.\n- Poor metabolizer (PM) corresponds to the homozygous loss-of-function genotype $\\ast 2 / \\ast 2$, thus proportion $q^{2} = 0.0225$.\n\nRounding to four significant figures:\n- IM: $0.255 \\rightarrow 0.2550$.\n- PM: $0.0225 \\rightarrow 0.02250$ (the trailing zero clarifies four significant figures).\n\nReport as a $1 \\times 2$ row in the order $\\text{IM}, \\text{PM}$.", "answer": "$$\\boxed{\\begin{pmatrix}0.2550 & 0.02250\\end{pmatrix}}$$", "id": "4327675"}, {"introduction": "The central mechanism of *CYP2C19* pharmacogenomics is that a loss-of-function allele impairs the bioactivation of clopidogrel, but by how much? Pharmacokinetic modeling provides a powerful framework for quantifying this relationship. In this practice [@problem_id:4327641], you will use a simplified compartmental model to calculate the direct impact of a genetically-driven reduction in enzyme activity on the steady-state concentration of clopidogrel's active metabolite, clarifying the precise biochemical consequence of the genotype.", "problem": "A widely used antiplatelet prodrug requires bioactivation by Cytochrome P450 2C19 (CYP2C19) to form its active thiol metabolite. Consider a patient receiving once-daily oral dosing with dose amount $D$ at interval $\\tau = 24 \\ \\mathrm{h}$. Model the system with two linked compartments under linear kinetics: a parent compartment with amount $A_{P}(t)$ and an active metabolite compartment with amount $A_{M}(t)$. The parent undergoes two parallel, first-order loss processes: CYP2C19-mediated bioactivation with rate constant $k_{f}$ and all other parent clearance with rate constant $k_{o}$. The active metabolite is formed from the parent at rate $k_{f} A_{P}(t)$ and eliminated with first-order rate constant $k_{m}$. The active metabolite concentration is $C_{M}(t) = A_{M}(t)/V_{m}$ in a fixed apparent volume $V_{m}$. Between dosing instants, the ordinary differential equations (ODEs) are\n$$\n\\frac{dA_{P}}{dt} = -\\left(k_{f} + k_{o}\\right) A_{P}(t), \n\\quad\n\\frac{dA_{M}}{dt} = k_{f} A_{P}(t) - k_{m} A_{M}(t),\n$$\nwith instantaneous bolus input $A_{P}(t^{+}) = A_{P}(t^{-}) + D$ at each dosing time.\n\nStart from mass balance and linear first-order kinetics and derive the expression for the steady-state interval-average active metabolite concentration $\\overline{C}_{M} = \\frac{1}{\\tau} \\int_{t}^{t+\\tau} C_{M}(s) \\, ds$ over one dosing interval. Then, suppose a loss-of-function (LOF) allele in CYP2C19 reduces the formation rate constant by $50\\%$ (i.e., $k_{f} \\to k_{f}/2$) with all other parameters unchanged. Using the following parameter values for the baseline (no LOF) state,\n- $D = 75 \\ \\mathrm{mg}$,\n- $\\tau = 24 \\ \\mathrm{h}$,\n- $k_{f} = 0.20 \\ \\mathrm{h}^{-1}$,\n- $k_{o} = 1.80 \\ \\mathrm{h}^{-1}$,\n- $k_{m} = 1.00 \\ \\mathrm{h}^{-1}$,\n- $V_{m} = 50 \\ \\mathrm{L}$,\ncompute the fold-change (ratio) in the steady-state interval-average active metabolite concentration $\\overline{C}_{M}$ produced by the $50\\%$ reduction in $k_{f}$.\n\nExpress the final fold-change as a decimal fraction. Round your answer to four significant figures. No units are required for the fold-change.", "solution": "The first step is to derive a general expression for the steady-state interval-average active metabolite concentration, $\\overline{C}_{M}$. This can be achieved efficiently by using a mass-balance approach, integrating the governing ordinary differential equations (ODEs) over a single dosing interval $\\tau$ at steady-state.\n\nLet the total elimination rate constant for the parent drug be $k_p = k_f + k_o$. The system of ODEs is:\n$$\n\\frac{dA_{P}}{dt} = -k_p A_{P}(t)\n$$\n$$\n\\frac{dA_{M}}{dt} = k_{f} A_{P}(t) - k_{m} A_{M}(t)\n$$\nAt steady state, the amount of any substance in a compartment at the end of a dosing interval is equal to the amount at the start of the next interval. Let's consider a single interval from $t=0$ to $t=\\tau$.\n\nFor the parent drug, the amount just after the dose at $t=0$ is $A_{P,ss}(0)$ and the amount just before the next dose at $t=\\tau$ is $A_{P,ss}(\\tau)$. The dosing is an instantaneous bolus, so $A_{P,ss}(0) = A_{P,ss}(\\tau) + D$.\nIntegrating the ODE for the parent drug over the interval $[0, \\tau]$:\n$$\n\\int_{0}^{\\tau} \\frac{dA_{P}}{dt} dt = \\int_{0}^{\\tau} -k_p A_{P}(t) dt\n$$\n$$\nA_{P,ss}(\\tau) - A_{P,ss}(0) = -k_p \\int_{0}^{\\tau} A_{P}(t) dt\n$$\nSubstituting $A_{P,ss}(0) = A_{P,ss}(\\tau) + D$, the left side becomes $A_{P,ss}(\\tau) - (A_{P,ss}(\\tau) + D) = -D$.\nThe integral on the right is the area under the amount-time curve for the parent drug over one interval at steady state, denoted $AUC_{P,ss,\\tau}$.\n$$\n-D = -k_p AUC_{P,ss,\\tau}\n$$\nThis gives:\n$$\nAUC_{P,ss,\\tau} = \\frac{D}{k_p} = \\frac{D}{k_f + k_o}\n$$\n\nFor the active metabolite, the steady-state condition is that the amount at the start of the interval equals the amount at the end: $A_{M,ss}(0) = A_{M,ss}(\\tau)$.\nIntegrating the ODE for the active metabolite over the interval $[0, \\tau]$:\n$$\n\\int_{0}^{\\tau} \\frac{dA_{M}}{dt} dt = \\int_{0}^{\\tau} \\left( k_{f} A_{P}(t) - k_{m} A_{M}(t) \\right) dt\n$$\n$$\nA_{M,ss}(\\tau) - A_{M,ss}(0) = k_{f} \\int_{0}^{\\tau} A_{P}(t) dt - k_{m} \\int_{0}^{\\tau} A_{M}(t) dt\n$$\nThe left side is zero due to the steady-state condition. Let $AUC_{M,ss,\\tau} = \\int_{0}^{\\tau} A_{M}(t) dt$.\n$$\n0 = k_f AUC_{P,ss,\\tau} - k_m AUC_{M,ss,\\tau}\n$$\nThis yields a relationship between the metabolite and parent AUCs:\n$$\nAUC_{M,ss,\\tau} = \\frac{k_f}{k_m} AUC_{P,ss,\\tau}\n$$\nSubstituting the expression for $AUC_{P,ss,\\tau}$:\n$$\nAUC_{M,ss,\\tau} = \\frac{k_f}{k_m} \\frac{D}{k_f + k_o}\n$$\nThe problem asks for the interval-average *concentration* $\\overline{C}_M$. This is defined as $\\overline{C}_{M} = \\frac{1}{\\tau} \\int_{0}^{\\tau} C_{M}(s) \\, ds$. Since $C_{M}(t) = A_{M}(t)/V_{m}$:\n$$\n\\overline{C}_{M} = \\frac{1}{\\tau} \\int_{0}^{\\tau} \\frac{A_{M}(s)}{V_m} ds = \\frac{1}{\\tau V_m} \\int_{0}^{\\tau} A_{M}(s) ds = \\frac{AUC_{M,ss,\\tau}}{\\tau V_m}\n$$\nSubstituting the expression for $AUC_{M,ss,\\tau}$:\n$$\n\\overline{C}_{M} = \\frac{1}{\\tau V_m} \\left( \\frac{k_f D}{k_m(k_f + k_o)} \\right) = \\frac{D}{\\tau V_m k_m} \\frac{k_f}{k_f + k_o}\n$$\nThis is the general expression for the steady-state average active metabolite concentration.\n\nNext, we compute the fold-change. Let $\\overline{C}_{M, \\text{base}}$ be the concentration for the baseline parameters and $\\overline{C}_{M, \\text{LOF}}$ be the concentration for the loss-of-function (LOF) case. In the LOF case, $k_f$ is replaced by $k_{f, \\text{LOF}} = k_f / 2 = 0.5 k_f$. All other parameters ($D, \\tau, V_m, k_m, k_o$) are unchanged.\n\nThe fold-change is the ratio $\\frac{\\overline{C}_{M, \\text{LOF}}}{\\overline{C}_{M, \\text{base}}}$.\n$$\n\\text{Fold-change} = \\frac{\\frac{D}{\\tau V_m k_m} \\frac{k_{f, \\text{LOF}}}{k_{f, \\text{LOF}} + k_o}}{\\frac{D}{\\tau V_m k_m} \\frac{k_f}{k_f + k_o}}\n$$\nThe constant pre-factor $\\frac{D}{\\tau V_m k_m}$ cancels out:\n$$\n\\text{Fold-change} = \\frac{\\frac{k_{f, \\text{LOF}}}{k_{f, \\text{LOF}} + k_o}}{\\frac{k_f}{k_f + k_o}} = \\frac{k_{f, \\text{LOF}}}{k_f} \\cdot \\frac{k_f + k_o}{k_{f, \\text{LOF}} + k_o}\n$$\nSubstituting $k_{f, \\text{LOF}} = k_f/2$:\n$$\n\\text{Fold-change} = \\frac{k_f/2}{k_f} \\cdot \\frac{k_f + k_o}{k_f/2 + k_o} = \\frac{1}{2} \\frac{k_f + k_o}{\\frac{1}{2}k_f + k_o}\n$$\nNow, we substitute the given numerical values for the baseline parameters:\n- $k_f = 0.20 \\ \\mathrm{h}^{-1}$\n- $k_o = 1.80 \\ \\mathrm{h}^{-1}$\n\n$$\n\\text{Fold-change} = \\frac{1}{2} \\cdot \\frac{0.20 + 1.80}{\\frac{1}{2}(0.20) + 1.80}\n$$\n$$\n\\text{Fold-change} = \\frac{1}{2} \\cdot \\frac{2.00}{0.10 + 1.80}\n$$\n$$\n\\text{Fold-change} = \\frac{1}{2} \\cdot \\frac{2.00}{1.90} = \\frac{1.00}{1.90}\n$$\n$$\n\\text{Fold-change} = \\frac{1}{1.9} = \\frac{10}{19}\n$$\nCalculating the decimal value:\n$$\n\\frac{10}{19} \\approx 0.526315789...\n$$\nRounding to four significant figures, we get $0.5263$.", "answer": "$$\\boxed{0.5263}$$", "id": "4327641"}, {"introduction": "Ultimately, the decision to implement widespread pharmacogenomic testing depends on its ability to improve patient outcomes on a population scale. This final exercise [@problem_id:4327633] synthesizes genetics, pharmacology, and epidemiology to evaluate the clinical utility of a *CYP2C19*-guided antiplatelet therapy strategy. By calculating the expected absolute reduction in major adverse cardiovascular events, you will learn how to build a quantitative argument for the adoption of precision medicine, taking into account factors like test accuracy, physician adherence, and the differential risks across patient subgroups.", "problem": "A hospital system is considering adoption of Clinical Pharmacogenetics Implementation Consortium (CPIC)-guided antiplatelet therapy for patients receiving clopidogrel, with genotyping for Cytochrome P450 Family 2 Subfamily C Member 19 (CYP2C19) loss-of-function alleles to identify intermediate metabolizers and poor metabolizers. Assume a one-year horizon for major adverse cardiovascular events (MACE), defined here as a composite of non-fatal myocardial infarction, stroke, stent thrombosis, or cardiovascular death.\n\nUse the following scientifically plausible and self-consistent assumptions, grounded in standard epidemiological definitions of absolute risk, relative risk, and expected value:\n\n- The baseline one-year event probabilities under uniform clopidogrel therapy (i.e., without pharmacogenomic guidance) are:\n  - Normal metabolizer (NM): $p_{\\mathrm{NM}} = 0.06$.\n  - Intermediate metabolizer (IM): $p_{\\mathrm{IM}} = 0.10$.\n  - Poor metabolizer (PM): $p_{\\mathrm{PM}} = 0.16$.\n- The phenotype distribution in the target population is:\n  - $r_{\\mathrm{NM}} = 0.68$, $r_{\\mathrm{IM}} = 0.27$, $r_{\\mathrm{PM}} = 0.05$, with $r_{\\mathrm{NM}} + r_{\\mathrm{IM}} + r_{\\mathrm{PM}} = 1$.\n- Under CPIC-guided therapy, IM and PM patients who are identified by genotyping and for whom clinicians implement alternative therapy (e.g., prasugrel or ticagrelor) experience relative risk reductions (RRR) in one-year MACE compared to their baseline clopidogrel risk:\n  - IM relative risk reduction: $\\mathrm{RRR}_{\\mathrm{IM}} = 0.25$.\n  - PM relative risk reduction: $\\mathrm{RRR}_{\\mathrm{PM}} = 0.45$.\n- The CYP2C19 genotyping test has sensitivity $s = 0.97$ for detecting loss-of-function alleles that confer IM or PM phenotypes, and specificity $\\mathrm{sp} = 0.995$ for correctly classifying NM status. Clinicians adopt the alternative therapy with probability $u = 0.92$ when a loss-of-function phenotype is reported.\n- For NM patients, receiving alternative therapy due to false positive classification does not change the one-year MACE risk compared to clopidogrel; that is, their risk remains $p_{\\mathrm{NM}}$ under either therapy for the purposes of this calculation.\n\nStarting from the definitions of absolute risk and expected value across strata, compute the expected absolute reduction in the one-year MACE probability for the population when adopting CPIC-guided therapy compared to uniform clopidogrel therapy. Express your final answer as a decimal proportion. Round your answer to four significant figures.", "solution": "The objective is to compute the expected absolute reduction in the one-year major adverse cardiovascular events (MACE) probability for the population. This is the difference between the expected MACE probability under uniform clopidogrel therapy (the standard strategy) and the expected MACE probability under CPIC-guided therapy (the new strategy). Let this quantity be $\\mathrm{ARR}_{\\mathrm{pop}}$.\n\n$\\mathrm{ARR}_{\\mathrm{pop}} = E[\\text{risk}]_{\\text{standard}} - E[\\text{risk}]_{\\text{guided}}$\n\nFirst, we calculate the expected MACE probability under the standard strategy of uniform clopidogrel therapy. This is the weighted average of the baseline MACE probabilities for each phenotype, where the weights are the respective population frequencies ($r_{\\mathrm{NM}}$, $r_{\\mathrm{IM}}$, $r_{\\mathrm{PM}}$).\n\n$E[\\text{risk}]_{\\text{standard}} = p_{\\mathrm{NM}} r_{\\mathrm{NM}} + p_{\\mathrm{IM}} r_{\\mathrm{IM}} + p_{\\mathrm{PM}} r_{\\mathrm{PM}}$\n\nNext, we calculate the expected MACE probability under the CPIC-guided strategy. This requires determining the new expected risk for each phenotype subgroup, which we denote as $p'_{\\mathrm{NM}}$, $p'_{\\mathrm{IM}}$, and $p'_{\\mathrm{PM}}$. The overall expected risk is then the weighted average of these new risks.\n\n$E[\\text{risk}]_{\\text{guided}} = p'_{\\mathrm{NM}} r_{\\mathrm{NM}} + p'_{\\mathrm{IM}} r_{\\mathrm{IM}} + p'_{\\mathrm{PM}} r_{\\mathrm{PM}}$\n\nLet's analyze the new expected risk for each subgroup:\n\nFor Normal Metabolizers (NM):\nAn NM patient has a true negative status for loss-of-function alleles.\n- With probability $\\mathrm{sp}$ (specificity), the test is correctly negative. The patient receives clopidogrel, and the risk is $p_{\\mathrm{NM}}$.\n- With probability $1 - \\mathrm{sp}$, the test is falsely positive.\n  - With probability $u$, the clinician adopts alternative therapy. The problem states the risk remains $p_{\\mathrm{NM}}$.\n  - With probability $1-u$, the clinician does not adopt alternative therapy. The risk is $p_{\\mathrm{NM}}$.\nIn all scenarios, the risk for an NM patient remains $p_{\\mathrm{NM}}$.\nTherefore, the new expected risk for the NM group is unchanged:\n$p'_{\\mathrm{NM}} = p_{\\mathrm{NM}}$\n\nFor Intermediate (IM) and Poor (PM) Metabolizers:\nThese patients have a true positive status for loss-of-function alleles. Let's derive a general formula for a phenotype `pheno` $\\in \\{\\mathrm{IM}, \\mathrm{PM}\\}$.\n- With probability $s$ (sensitivity), the test is correctly positive.\n  - With probability $u$, the clinician adopts alternative therapy. The risk is reduced by the relative risk reduction, RRR. The new risk is $p_{\\text{pheno}}(1 - \\mathrm{RRR}_{\\text{pheno}})$.\n  - With probability $1-u$, the clinician does not adopt the new therapy. The risk remains the baseline, $p_{\\text{pheno}}$.\n- With probability $1-s$, the test is falsely negative. The patient receives clopidogrel, and the risk remains $p_{\\text{pheno}}$.\n\nThe new expected risk, $p'_{\\text{pheno}}$, is the sum of probabilities of all scenarios multiplied by their respective risks:\n$p'_{\\text{pheno}} = s \\cdot u \\cdot p_{\\text{pheno}}(1 - \\mathrm{RRR}_{\\text{pheno}}) + s \\cdot (1-u) \\cdot p_{\\text{pheno}} + (1-s) \\cdot p_{\\text{pheno}}$\nFactoring out $p_{\\text{pheno}}$:\n$p'_{\\text{pheno}} = p_{\\text{pheno}} [s \\cdot u \\cdot (1 - \\mathrm{RRR}_{\\text{pheno}}) + s \\cdot (1-u) + (1-s)]$\n$p'_{\\text{pheno}} = p_{\\text{pheno}} [s \\cdot u - s \\cdot u \\cdot \\mathrm{RRR}_{\\text{pheno}} + s - s \\cdot u + 1 - s]$\n$p'_{\\text{pheno}} = p_{\\text{pheno}} [1 - s \\cdot u \\cdot \\mathrm{RRR}_{\\text{pheno}}]$\n\nNow we can write the expression for the total population absolute risk reduction:\n$\\mathrm{ARR}_{\\mathrm{pop}} = (p_{\\mathrm{NM}} r_{\\mathrm{NM}} + p_{\\mathrm{IM}} r_{\\mathrm{IM}} + p_{\\mathrm{PM}} r_{\\mathrm{PM}}) - (p'_{\\mathrm{NM}} r_{\\mathrm{NM}} + p'_{\\mathrm{IM}} r_{\\mathrm{IM}} + p'_{\\mathrm{PM}} r_{\\mathrm{PM}})$\n\nSubstitute the expressions for $p'_{\\mathrm{NM}}$, $p'_{\\mathrm{IM}}$, and $p'_{\\mathrm{PM}}$:\n$\\mathrm{ARR}_{\\mathrm{pop}} = (p_{\\mathrm{NM}} r_{\\mathrm{NM}} + p_{\\mathrm{IM}} r_{\\mathrm{IM}} + p_{\\mathrm{PM}} r_{\\mathrm{PM}}) - [p_{\\mathrm{NM}} r_{\\mathrm{NM}} + p_{\\mathrm{IM}}(1 - s \\cdot u \\cdot \\mathrm{RRR}_{\\mathrm{IM}}) r_{\\mathrm{IM}} + p_{\\mathrm{PM}}(1 - s \\cdot u \\cdot \\mathrm{RRR}_{\\mathrm{PM}}) r_{\\mathrm{PM}}]$\n\nThe term $p_{\\mathrm{NM}} r_{\\mathrm{NM}}$ cancels out, as the risk and management for correctly identified NMs do not change, and the risk for misclassified NMs is also assumed not to change.\n$\\mathrm{ARR}_{\\mathrm{pop}} = (p_{\\mathrm{IM}} r_{\\mathrm{IM}} - p_{\\mathrm{IM}}(1 - s \\cdot u \\cdot \\mathrm{RRR}_{\\mathrm{IM}}) r_{\\mathrm{IM}}) + (p_{\\mathrm{PM}} r_{\\mathrm{PM}} - p_{\\mathrm{PM}}(1 - s \\cdot u \\cdot \\mathrm{RRR}_{\\mathrm{PM}}) r_{\\mathrm{PM}})$\n$\\mathrm{ARR}_{\\mathrm{pop}} = (p_{\\mathrm{IM}} r_{\\mathrm{IM}} - p_{\\mathrm{IM}} r_{\\mathrm{IM}} + p_{\\mathrm{IM}} r_{\\mathrm{IM}} s \\cdot u \\cdot \\mathrm{RRR}_{\\mathrm{IM}}) + (p_{\\mathrm{PM}} r_{\\mathrm{PM}} - p_{\\mathrm{PM}} r_{\\mathrm{PM}} + p_{\\mathrm{PM}} r_{\\mathrm{PM}} s \\cdot u \\cdot \\mathrm{RRR}_{\\mathrm{PM}})$\n\nThis simplifies to a very intuitive result: the total risk reduction is the sum of the risk reductions achieved in the IM and PM populations.\n$\\mathrm{ARR}_{\\mathrm{pop}} = p_{\\mathrm{IM}} r_{\\mathrm{IM}} s \\cdot u \\cdot \\mathrm{RRR}_{\\mathrm{IM}} + p_{\\mathrm{PM}} r_{\\mathrm{PM}} s \\cdot u \\cdot \\mathrm{RRR}_{\\mathrm{PM}}$\n\nNow, we substitute the given numerical values:\n- $p_{\\mathrm{IM}} = 0.10$\n- $r_{\\mathrm{IM}} = 0.27$\n- $s = 0.97$\n- $u = 0.92$\n- $\\mathrm{RRR}_{\\mathrm{IM}} = 0.25$\n- $p_{\\mathrm{PM}} = 0.16$\n- $r_{\\mathrm{PM}} = 0.05$\n- $\\mathrm{RRR}_{\\mathrm{PM}} = 0.45$\n\n$\\mathrm{ARR}_{\\mathrm{pop}} = (0.10 \\times 0.27 \\times 0.97 \\times 0.92 \\times 0.25) + (0.16 \\times 0.05 \\times 0.97 \\times 0.92 \\times 0.45)$\n\nFirst term (contribution from IM group):\n$0.10 \\times 0.27 \\times 0.97 \\times 0.92 \\times 0.25 = 0.0060237$\n\nSecond term (contribution from PM group):\n$0.16 \\times 0.05 \\times 0.97 \\times 0.92 \\times 0.45 = 0.00321264$\n\nTotal absolute risk reduction:\n$\\mathrm{ARR}_{\\mathrm{pop}} = 0.0060237 + 0.00321264 = 0.00923634$\n\nThe problem requires the answer to be rounded to four significant figures.\n$\\mathrm{ARR}_{\\mathrm{pop}} \\approx 0.009236$\n\nThe expected absolute reduction in the one-year MACE probability is $0.009236$.", "answer": "$$\n\\boxed{0.009236}\n$$", "id": "4327633"}]}